ro 22-1319 has been researched along with metoclopramide in 2 studies
| Studies (ro 22-1319) | Trials (ro 22-1319) | Recent Studies (post-2010) (ro 22-1319) | Studies (metoclopramide) | Trials (metoclopramide) | Recent Studies (post-2010) (metoclopramide) |
|---|---|---|---|---|---|
| 23 | 3 | 0 | 5,044 | 1,216 | 623 |
| Protein | Taxonomy | ro 22-1319 (IC50) | metoclopramide (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 2.383 | |
| Myeloperoxidase | Homo sapiens (human) | 0.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.721 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.127 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 7.8 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.7 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.675 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 2.383 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 7.8 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.2 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.88 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.63 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.8 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6237 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.88 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collin, S; Durant, F; Evrard, G; Vanderveken, D; Vercauteren, DP | 1 |
| Molloy, AG; O'Boyle, KM; Pugh, MT; Waddington, JL | 1 |
2 other study(ies) available for ro 22-1319 and metoclopramide
| Article | Year |
|---|---|
Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands.
Topics: Computer Graphics; Dopamine Antagonists; Imidazoles; Isoquinolines; Metoclopramide; Models, Molecular; Motion; Nortropanes; Receptors, Dopamine; Sodium; Structure-Activity Relationship | 1989 |
Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Flupenthixol; Isoquinolines; Male; Metoclopramide; Motor Activity; Phenethylamines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stimulation, Chemical | 1986 |